This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Contents — quick navigation | ||
|---|---|---|
| A | Basic information | ICD-10: G40.4 | Special Copayment Reduction: V233 | Coverage period: 5 years |
| B | Synonyms | Infantile spasms, infantile epileptic spasms, Blitz-Nick-Salaam-Krämpfe |
| C | Adult onset | Possibility of first manifestation in adulthood: very low — onset at 3-12 months of age; no adult-onset cases reported |
| S1 | History | From William West's first description in 1841 to the establishment of the hypsarrhythmia concept |
| S2 | Causes | Structural (40%), metabolic (10%), genetic (15%), unknown cause (35%) |
| S3 | Genetics | Many genes involved, including TSC1/2, ARX, CDKL5, STXBP1 |
| S4 | General epidemiology | Incidence 1 in 2,000-4,000 live births; onset at 3-12 months of age |
| S5 | Pathophysiology | Brainstem-cortical circuit abnormality, ACTH-CRH axis overactivity, impaired synaptic development |
| S6 | Symptoms | Clusters of flexor and extensor spasm seizures, developmental regression, loss of social responsiveness |
| S7 | Signs | Hypsarrhythmia (high-amplitude disorganized background + multifocal spikes), seizure clusters |
| S8 | Screening | Prolonged video-EEG, brain MRI, metabolic screening, genetic testing |
| S9 | Diagnosis | Based on the clinical triad; ILAE 2022 infantile epileptic spasms syndrome criteria |
| S10 | Treatment | ACTH or vigabatrin as first-line treatment; prednisolone as an alternative |
| S11 | Prognosis | 50-60% of patients respond to treatment; 20-30% evolve to LGS; poor prognosis |
| S12 | Prevention | Early treatment of tuberous sclerosis, prevention of perinatal brain injury |
| S13 | References | 10 key references |
West syndrome appeared in history in 1841, when the English physician William James West first described, in a letter to The Lancet, a seizure syndrome he had observed in his son James. West described in detail the clinical pattern of 'repeated brief spasms in which the child bows his head forward', but at that time there was no effective treatment. This syndrome was also called 'Blitz-Nick-Salaam-Krämpfe (lightning-nodding-salaam spasms)' in Germany.
In 1952, Gibbs and Gibbs described the characteristic EEG pattern associated with these seizures and introduced the term 'hypsarrhythmia (high-amplitude disorganized EEG)'. The name derives from the Greek hypsos (height) and arrhythmia (irregularity) and refers to a disorganized EEG pattern in which high-amplitude polymorphic slow waves and multifocal spikes are mixed. Thus the triad of infantile spasms-hypsarrhythmia-developmental regression was established as the diagnostic criteria of the syndrome.
The era of drug treatment opened in 1958 when Sorel and Dusaucy-Bauloye first reported the therapeutic effect of ACTH (adrenocorticotropic hormone). In 1992, vigabatrin became known to be particularly effective for infantile spasms associated with tuberous sclerosis. The 2004 UK Infantile Spasms Study (UKISS) and the 2007 UKISS follow-up study compared the effects of ACTH and vigabatrin and provided evidence-based treatment guidelines. In 2022, the ILAE renamed this syndrome 'Infantile Epileptic Spasms Syndrome (IESS)', but clinically the name West syndrome is still widely used.
West syndrome is understood as a nonspecific syndrome in which the immature brain responds to various insults. By cause, it is classified into structural, metabolic, genetic, and unknown cause.
Cases in which the cause cannot be identified with current diagnostic technology; the cause of some of these is expected to be revealed in the future with more advanced genetic analysis.
With advances in next-generation genome analysis technology, the rate of identifying a genetic cause in West syndrome patients has improved greatly. When whole exome sequencing is applied, a genetic cause is identified in about 30-50% of patients.
| Gene | Mode of inheritance | Key features |
|---|---|---|
| TSC1/TSC2 | Autosomal dominant | Tuberous sclerosis; mTOR hyperactivation; cortical tubers |
| ARX | X-linked | Severe phenotype in males; brain structural abnormalities may accompany |
| CDKL5 | X-linked | Early-onset seizures, Rett syndrome-like phenotype |
| STXBP1 | Autosomal dominant (de novo) | Synaptic secretion disorder; overlaps with Ohtahara syndrome |
| SCN2A | Autosomal dominant (de novo) | Sodium channel dysfunction; early-onset epilepsy |
| KCNQ2 | Autosomal dominant (de novo) | Evolution from neonatal epilepsy to infantile spasms |
| SPTAN1 | Autosomal dominant (de novo) | Alpha-II-spectrin deficiency; severe phenotype |
Down syndrome (trisomy 21) is one of the important causes of infantile spasms, and infantile spasms occur in about 1-13% of infants with Down syndrome. Tuberous sclerosis is the most common single genetic cause among West syndrome cases with an identified cause, and vigabatrin is particularly effective in TSC-related infantile spasms. De novo mutations account for a considerable portion of genetic causes, so genetic testing is recommended even when the parents' phenotype is normal.
The incidence of West syndrome is estimated at about 2-5 per 10,000 population, or 1 per 2,000-4,000 live births. This is a relatively high incidence among childhood epilepsies.
The age at onset is typically 3-12 months, with a peak at 4-7 months. Onset after 12 months of age is uncommon, and first onset in adults is virtually unreported. It occurs slightly more often in boys (male:female = about 1.3:1).
By cause, cases with a structural cause (symptomatic West syndrome) are far more numerous than idiopathic or unknown-cause West syndrome. In the past they were divided into symptomatic and idiopathic, but the current ILAE classification subdivides them into structural, metabolic, genetic, and unknown cause.
According to epidemiological data in Korea, occurrence of infantile spasms related to perinatal brain injury continues to be reported owing to improved neonatal intensive care unit (NICU) survival. Owing to increased diagnosis rates of tuberous sclerosis, patients with TSC-related infantile spasms are also on the rise.
The pathogenesis of West syndrome is understood as brain injury from various causes, at a specific developmental period of the brain (early infancy), activating a common pathway that triggers spasm seizures.
The developing infant brain is in a state of hyperexcitability due to corticotropin-releasing hormone (CRH). Various brain injuries promote excessive CRH secretion, causing hyperexcitability of the hippocampus and amygdala. ACTH is thought to suppress seizures by antagonizing CRH receptors or promoting production of endogenous peptides. This theory explains the mechanism of ACTH treatment, but has not been fully validated.
An imbalance between the excitatory network of the brainstem and the immature cortical inhibitory circuit is proposed to explain the characteristic form of spasm seizures (sudden, brief flexor or extensor stiffening). In the early developing brain, GABAergic inhibition is immature and excitatory transmission predominates.
Abnormalities in the synaptic pruning process of the immature brain cause formation of abnormal neural circuits, which is the pathophysiological basis of hypsarrhythmia. The infantile characteristics of the GABA-A receptor (GABA acts as excitatory owing to reversal of the Cl- concentration gradient) also contribute to a lowered seizure threshold.
In tuberous sclerosis and some cortical malformations, hyperactivation of the mTOR signaling pathway causes cortical tuber formation and increased neuronal excitability. mTOR inhibitors (everolimus) show a seizure-suppressing effect in TSC-related infantile spasms.
The core clinical triad of West syndrome is infantile spasm seizures, hypsarrhythmia, and developmental regression.
Spasms are sudden, brief (1-5 seconds) muscle contractions that appear in the following forms.
Spasms are characterized by occurring in clusters. Within one cluster, several to dozens of spasms repeat over several minutes, with short intervals between clusters. They occur mainly on waking from sleep or when drowsy. Infants may cry after a spasm, which becomes a clue by which parents first notice an abnormality.
Developmental regression is observed before the onset of infantile spasms or in the early stage of seizures. Previously acquired developmental milestones (eye contact, smiling, reaching for objects, etc.) are lost. Decreased social interaction and autism-like behavior may appear. The speed and severity of developmental regression vary with the underlying disease and treatment response.
When there is a structural cause, neurological abnormalities according to the underlying disease (hypotonia, cranial nerve abnormalities, etc.) may precede. In patients with tuberous sclerosis, hypopigmented skin patches (ash-leaf spots) are observed from immediately after birth.
Hypsarrhythmia is the most characteristic EEG finding of West syndrome and is defined as follows.
The EEG correlate of a spasm seizure is characterized by widespread high-amplitude slow waves (electrodecrement) followed by low-amplitude fast activity. In some patients, infantile spasms occur even without typical hypsarrhythmia (modified hypsarrhythmia or atypical EEG).
The infantile spasms themselves are identified clinically as brief, repetitive flexor/extensor seizures. Hypotonia is commonly observed regardless of the underlying disease. In tuberous sclerosis-related West syndrome, skin findings (ash-leaf spots, angiofibromas on the cheeks) provide important clues for diagnosis.
When infantile spasms are suspected, prompt evaluation is essential, and the time from seizure onset to treatment affects prognosis.
Prolonged (at least 4-24 hours) video-EEG including wakefulness and sleep is essential for confirming hypsarrhythmia and the EEG correlate of infantile spasms. Because seizure clusters occur mainly on waking from sleep, EEG recording during the sleep-wake transition is important.
Brain MRI (3T, including a neonatal protocol) is performed to evaluate structural causes. Cortical malformations, cortical tubers (tuberous sclerosis), white matter abnormalities, and hypoxic-ischemic injury are identified.
Blood: glucose, lactate, ammonia, amino acid analysis. Urine: organic acids, creatine, adenylosuccinate. Cerebrospinal fluid: glucose (to confirm brain glucose transporter deficiency), glycine, neurotransmitter metabolites.
When the cause is unknown or a genetic cause is suspected, an infantile seizure gene panel or whole exome sequencing (trio approach recommended) is performed early.
Diagnosis of West syndrome is a clinical diagnosis based on the clinical triad. In the ILAE 2022 classification, the name was changed to 'Infantile Epileptic Spasms Syndrome (IESS)'.
| Disease | Distinguishing points |
|---|---|
| Neonatal seizures | Occur immediately after birth; patterns vary; no hypsarrhythmia |
| Benign myoclonic epilepsy of infancy | Myoclonic seizures; normal EEG background; good prognosis |
| Weiss syndrome | Startle response; no EEG seizure correlate |
| Infantile colic | Crying related to abdominal pain; normal EEG |
| Sandifer syndrome | Gastroesophageal reflux; neck extension; normal EEG |
Treatment of infantile spasms aims at rapid EEG response and clinical seizure cessation. Delay in treatment worsens developmental outcomes, so treatment is started immediately upon diagnosis.
When there is no response to monotherapy, or, in some guidelines, combined ACTH and vigabatrin is recommended from the start. The ICISS study (2017) reported that combination therapy had a higher rate of EEG resolution than monotherapy.
In focal infantile spasms due to a single lesion (cortical dysplasia, tuberous sclerosis tuber), lesion resection can be effective. Before surgical treatment, detailed evaluation such as PET, MEG, and intracranial EEG monitoring is needed.
The prognosis of West syndrome differs greatly depending on the underlying disease and treatment response.
Methods of directly preventing West syndrome itself are limited, but the following approaches can contribute to risk reduction.